Affimed (NASDAQ:AFMD) Short Interest Update

Affimed (NASDAQ:AFMD – Get Rating) was the target of a large increase in short interest in December. As of December 30th, there was short interest totalling 4,010,000 shares, an increase of 7.8% from the December 15th total of 3,720,000 shares. Based on an average daily volume of 2,100,000 shares, the short-interest ratio is currently 1.9 days.

Affimed Trading Up 4.3 %

AFMD opened at $1.22 on Monday. The firm has a market cap of $150.57 million, a price-to-earnings ratio of -1.94 and a beta of 2.35. The company has a current ratio of 5.65, a quick ratio of 5.63 and a debt-to-equity ratio of 0.07. Affimed has a 12 month low of $1.03 and a 12 month high of $5.10. The stock has a fifty day moving average price of $1.54 and a 200-day moving average price of $2.13.

Affimed (NASDAQ:AFMD – Get Rating) last released its quarterly earnings results on Tuesday, November 15th. The biopharmaceutical company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.08. Affimed had a negative return on equity of 48.46% and a negative net margin of 189.04%. The firm had revenue of $15.01 million during the quarter, compared to analyst estimates of $7.66 million. As a group, equities research analysts anticipate that Affimed will post -0.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. 683 Capital Management LLC grew its stake in Affimed by 8.9% during the 3rd quarter. 683 Capital Management LLC now owns 8,350,000 shares of the biopharmaceutical company’s stock worth $17,202,000 after buying an additional 685,000 shares during the last quarter. Woodline Partners LP purchased a new position in Affimed during the 2nd quarter worth $6,953,000. State Street Corp grew its stake in Affimed by 5.0% during the 3rd quarter. State Street Corp now owns 2,355,701 shares of the biopharmaceutical company’s stock worth $4,853,000 after buying an additional 112,217 shares during the last quarter. Vanguard Group Inc. grew its stake in Affimed by 14.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,398,231 shares of the biopharmaceutical company’s stock worth $2,880,000 after buying an additional 171,258 shares during the last quarter. Finally, Bain Capital Public Equity Management II LLC grew its stake in Affimed by 118.8% during the 2nd quarter. Bain Capital Public Equity Management II LLC now owns 1,274,153 shares of the biopharmaceutical company’s stock worth $3,529,000 after buying an additional 691,817 shares during the last quarter. 61.73% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on AFMD. Piper Sandler decreased their target price on Affimed from $7.00 to $6.00 and set an “overweight” rating for the company in a research report on Monday, December 12th. Truist Financial decreased their target price on Affimed from $12.00 to $8.00 in a research report on Monday, December 12th. Stifel Nicolaus lowered Affimed from a “buy” rating to a “hold” rating and decreased their target price for the company from $9.00 to $2.00 in a research report on Monday, October 10th. Wells Fargo & Company decreased their target price on Affimed from $8.00 to $7.00 and set an “overweight” rating for the company in a research report on Monday, December 12th. Finally, StockNews.com raised Affimed from a “sell” rating to a “hold” rating in a research report on Monday, November 21st. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, Affimed presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.71.

About Affimed

(Get Rating)

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma.